Yahoo Finance Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) insiders placed bullish bets worth US$1.0m in the last 12 months
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in Sensei Biotherapeutics, Inc.'s (NASDAQ:SNSE) instance, it's good news for shareholders.
While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.
View our latest analysis for Sensei Biotherapeutics
Sensei Biotherapeutics Insider Transactions Over The Last Year
In the last twelve months, the biggest single sale by an insider was when the Chief R&D Officer, Robert Pierce, sold US$568k worth of shares at a price of US$7.13 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The silver lining is that this sell-down took place above the latest price (US$5.24). So it may not tell us anything about how insiders feel about the current share price. Robert Pierce was the only individual insider to sell over the last year.
Happily, we note that in the last year insiders paid US$1.0m for 181.92k shares. On the other hand they divested 95.82k shares, for US$686k. In the last twelve months there was more buying than selling by Sensei Biotherapeutics insiders. They paid about US$5.58 on average. These transactions suggest that insiders have considered the current price attractive. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Sensei Biotherapeutics Insiders Bought Stock Recently
Over the last quarter, Sensei Biotherapeutics insiders have spent a meaningful amount on shares. Overall, two insiders shelled out US$951k for shares in the company -- and none sold. This could be interpreted as suggesting a positive outlook.
Insider Ownership of Sensei Biotherapeutics
Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Sensei Biotherapeutics insiders own about US$29m worth of shares. That equates to 18% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
What Might The Insider Transactions At Sensei Biotherapeutics Tell Us?
The recent insider purchases are heartening. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Given that insiders also own a fair bit of Sensei Biotherapeutics we think they are probably pretty confident of a bright future. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. When we did our research, we found 4 warning signs for Sensei Biotherapeutics (2 shouldn't be ignored!) that we believe deserve your full attention.
Of course Sensei Biotherapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
